SC
ITCI

Samlyn Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Samlyn Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-537,888
Closed -$25M – 115
2022
Q3 		$25M Buy
537,888
+75,073
+16% +$3.92M 0.47% 58
2022
Q2 		$26.4M Sell
462,815
-21,288
-4% -$1.21M 0.53% 48
2022
Q1 		$29.6M Sell
484,103
-625,752
-56% -$32.5M 0.43% 60
2021
Q4 		$58.1M Sell
1,109,855
-153,861
-12% -$6.46M 0.8% 40
2021
Q3 		$47.1M Buy
1,263,716
+136,101
+12% +$4.73M 0.63% 46
2021
Q2 		$46M Sell
1,127,615
-241,991
-18% -$8.94M 0.68% 44
2021
Q1 		$46.5M Sell
1,369,606
-290,332
-17% -$10.1M 0.64% 46
2020
Q4 		$52.8M Sell
1,659,938
-72,427
-4% -$1.9M 0.76% 43
2020
Q3 		$44.5M Buy
1,732,365
+553,798
+47% +$12.6M 0.8% 44
2020
Q2 		$30.3M Buy
1,178,567
+25,171
+2% +$510K 0.56% 57
2020
Q1 		$17.7M Buy
1,153,396
+886,696
+332% +$19.3M 0.45% 55
2019
Q4 		$9.15M Sell
266,700
-912,983
-77% -$11M 0.19% 79
2019
Q3 		$8.81M Buy
1,179,683
+147,578
+14% +$1.41M 0.21% 80
2019
Q2 		$13.4M Sell
1,032,105
-330,981
-24% -$4.24M 0.28% 83
2019
Q1 		$16.6M Buy
1,363,086
+96,948
+8% +$1.24M 0.39% 70
2018
Q4 		$14.4M Buy
1,266,138
+494,918
+64% +$7.99M 0.34% 74
2018
Q3 		$16.7M Sell
771,220
-219,061
-22% -$4.58M 0.38% 84
2018
Q2 		$17.5M Buy
990,281
+335,938
+51% +$6.82M 0.41% 79
2018
Q1 		$13.8M Sell
654,343
-350,413
-35% -$6.83M 0.3% 83
2017
Q4 		$14.5M Buy
1,004,756
+255,077
+34% +$3.94M 0.33% 84
2017
Q3 		$11.8M Buy
749,679
+212,479
+40% +$3.12M 0.3% 83
2017
Q2 		$6.67M Buy
537,200
+198,700
+59% +$2.3M 0.16% 93
2017
Q1 		$5.5M Buy
+338,500
New +$4.9M 0.13% 115

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Samlyn Capital's ITCI Position: Q4 2022 in Review

Samlyn Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2022, closing a stake of 537,888 shares — an estimated $25M sold.

Samlyn Capital first reported a position in ITCI in Q1 2017 and held it in 23 quarters. The position peaked at $58.1M in Q4 2021. 283 funds tracked by Wall St. Rank hold ITCI as of Q4 2022.

  • Samlyn Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2022 after selling out during the quarter.
  • Samlyn Capital sold 537,888 Intra-Cellular Therapies Inc. shares in Q4 2022, an estimated $25M.
  • Samlyn Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2017 and held it in 23 quarters.
  • Samlyn Capital's Intra-Cellular Therapies Inc. position peaked at $58.1M in Q4 2021.
  • 283 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2022.

Based on Samlyn Capital's 13F filing for Q4 2022, filed 14 Feb 2023.